Mary C Playdon, Sheetal Hardikar, Prasoona Karra, Rachel Hoobler, Anna R Ibele, Katherine L Cook, Amanika Kumar, Joseph E Ippolito, Justin C Brown
{"title":"代谢和减肥手术以及预防癌症的肥胖症药物疗法:现状和未来的可能性。","authors":"Mary C Playdon, Sheetal Hardikar, Prasoona Karra, Rachel Hoobler, Anna R Ibele, Katherine L Cook, Amanika Kumar, Joseph E Ippolito, Justin C Brown","doi":"10.1093/jncimonographs/lgad003","DOIUrl":null,"url":null,"abstract":"<p><p>Obesity is a chronic, relapsing, progressive disease of excess adiposity that increases the risk of developing at least 13 types of cancer. This report provides a concise review of the current state of the science regarding metabolic and bariatric surgery and obesity pharmacotherapy related to cancer risk. Meta-analyses of cohort studies report that metabolic and bariatric surgery is independently associated with a lower risk of incident cancer than nonsurgical obesity care. Less is known regarding the cancer-preventive effects of obesity pharmacotherapy. The recent approval and promising pipeline of obesity drugs will provide the opportunity to understand the potential for obesity therapy to emerge as an evidence-based cancer prevention strategy. There are myriad research opportunities to advance our understanding of how metabolic and bariatric surgery and obesity pharmacotherapy may be used for cancer prevention.</p>","PeriodicalId":73988,"journal":{"name":"Journal of the National Cancer Institute. Monographs","volume":"2023 61","pages":"68-76"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157771/pdf/","citationCount":"0","resultStr":"{\"title\":\"Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: current status and future possibilities.\",\"authors\":\"Mary C Playdon, Sheetal Hardikar, Prasoona Karra, Rachel Hoobler, Anna R Ibele, Katherine L Cook, Amanika Kumar, Joseph E Ippolito, Justin C Brown\",\"doi\":\"10.1093/jncimonographs/lgad003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Obesity is a chronic, relapsing, progressive disease of excess adiposity that increases the risk of developing at least 13 types of cancer. This report provides a concise review of the current state of the science regarding metabolic and bariatric surgery and obesity pharmacotherapy related to cancer risk. Meta-analyses of cohort studies report that metabolic and bariatric surgery is independently associated with a lower risk of incident cancer than nonsurgical obesity care. Less is known regarding the cancer-preventive effects of obesity pharmacotherapy. The recent approval and promising pipeline of obesity drugs will provide the opportunity to understand the potential for obesity therapy to emerge as an evidence-based cancer prevention strategy. There are myriad research opportunities to advance our understanding of how metabolic and bariatric surgery and obesity pharmacotherapy may be used for cancer prevention.</p>\",\"PeriodicalId\":73988,\"journal\":{\"name\":\"Journal of the National Cancer Institute. Monographs\",\"volume\":\"2023 61\",\"pages\":\"68-76\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157771/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the National Cancer Institute. Monographs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/jncimonographs/lgad003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Institute. Monographs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jncimonographs/lgad003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: current status and future possibilities.
Obesity is a chronic, relapsing, progressive disease of excess adiposity that increases the risk of developing at least 13 types of cancer. This report provides a concise review of the current state of the science regarding metabolic and bariatric surgery and obesity pharmacotherapy related to cancer risk. Meta-analyses of cohort studies report that metabolic and bariatric surgery is independently associated with a lower risk of incident cancer than nonsurgical obesity care. Less is known regarding the cancer-preventive effects of obesity pharmacotherapy. The recent approval and promising pipeline of obesity drugs will provide the opportunity to understand the potential for obesity therapy to emerge as an evidence-based cancer prevention strategy. There are myriad research opportunities to advance our understanding of how metabolic and bariatric surgery and obesity pharmacotherapy may be used for cancer prevention.